Renal ca surgery often determined by doctors’ practice style

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

A new study shows that the type of surgery a patient with renal cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health (Miller et al: Cancer, published online March 10, 2008, DOI: 10.1002/cncr.23372).

A new study shows that the type of surgery a patient with renal cancer receives depends more on the surgeon’s preference than on the patient’s tumor size, demographic characteristics, or general medical health (Miller et al: Cancer, published online March 10, 2008, DOI: 10.1002/cncr.23372).

The findings suggest that patients with renal cancer often may not be receiving the most appropriate surgical care, said David Miller, MD, and colleagues from UCLA.

To investigate the potential barriers to adoption of partial nephrectomy and renal laparoscopy, Dr. Miller and his colleagues reviewed SEER and Medicare data to identify Medicare beneficiaries with localized renal cancer diagnosed between 1997 and 2002, determine the type of surgery received by each patient, and identify the primary surgeon for each case.

They found 611 patients who underwent partial nephrectomy and 4,872 who had radical nephrectomy, 515 of which were performed laparoscopically.

After taking into consideration factors including patient demographics, comorbidity, tumor size, and volume of surgeries done by each surgeon, the investigators found considerable variation among surgeons in the type of surgery they performed-an 18.1% variance for partial nephrectomy and a 37.4% variance for laparoscopy.

Factors based on surgeons’ practice style contributed more to these variances than did patient characteristics.

The authors concluded that “for many older patients with kidney cancer, the surgery provided may depend more on their surgeon’s practice style than on the characteristics of the patient and his or her disease.”

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content